World Journal of Endocrine Surgery

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 2 , ISSUE 2 ( May-August, 2010 ) > List of Articles

RESEARCH ARTICLE

Radioiodine is not the Preferred Choice of Treatment for Pediatric Graves' Disease

Sagili Vijaya Bhaskar Reddy

Citation Information : Reddy SV. Radioiodine is not the Preferred Choice of Treatment for Pediatric Graves' Disease. World J Endoc Surg 2010; 2 (2):81-85.

DOI: 10.5005/jp-journals-10002-1027

Published Online: 01-04-2013

Copyright Statement:  Copyright © 2010; The Author(s).


Abstract

Radioactive iodine (RAI) ablation for treatment of hyperthyroidism in Pediatric Graves' disease is effective but limited literature exists regarding its long-term safety. There is no long-term prospective randomized controlled study on long-term safety of pediatric Graves' disease receiving RAI ablation. There are concerns regarding development of both thyroid and non-thyroidal malignancy, and primary hyperparathyroidism in subjects receiving RAI. Current evidences donot support routine use of RAI ablation in such situation. Surgery is a safe option.

PDF Share
  1. Thyrotoxicosis in children. Endocrinol Metab Clin North Am 1998;27:109-25.
  2. Clinical review 99: The management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998;83:3767-76.
  3. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000;85:3678-82.
  4. Radioiodine treatment for pediatric Graves’ disease. Cochrane database Syst Rev 2008;3:CD006294.
  5. Biologic effects of radioiodines on the human thyroid gland. In: Braverman LE, Utiger RD (Eds). Werner and Ingbar's the Thyroid (8th ed). Philadelphia: Lippincott Williams and Wilkins 2000;345-54.
  6. Thyroid cancer after exposure to external radiation: A pooled analysis of seven studies. Radiation Research 1995;141:259-77.
  7. Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst 2005;96:724-32.
  8. Cancer incidence following treatment for hyperthyroidism. Int J Epidemiol 1982;11:218-24.
  9. Cancer risk after iodine- 131 therapy for hyperthyroidism. J Natl Cancer Inst 1991;83:1072-77.
  10. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 1998;280:347-55.
  11. Cancer incidence and mortaility after radioiodine treatment for hyperthyroidism: A population-based cohort study. Lancet 1999;353:2111-15.
  12. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 2007;109:1072-79.
  13. Second primary malignancy risk in thyroid cancer survivors: A systematic review and meta-analysis. Thyroid 2007;17:1277-88.
  14. Doseresponse relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab 1995;80:254-57.
  15. Hyperparathyroidism after radioactive iodine therapy for Graves disease. Surgery 1982;92:811-13.
  16. An evaluation of the incidence of hyperparathyroidism after 131I treatment for Basedow disease. Kaku Igaku 1996;33:729-35.
  17. Risk of parathyroid adenomas in patients with thyrotoxicosis exposed to radioactive iodine. Acta Oncologica 2006;45:1059-61.
  18. Hyperparathyroidism after radioactive iodine therapy. Am J Surg 2007;194:323-27.
  19. Irradiation of the thyroid as a cause of parathyroid adenoma. Lancet 1977;1:593-94.
  20. Experimental induction of parathyroid adenomas in the rat. J Natl Cancer Inst 1983;70:127-34.
  21. Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med 1975;292:167-71.
  22. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab 2004;89:4229-33.
  23. Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol 1994;131: 467-73.
  24. A questionnaire survey concerning the most favourable treatment for Graves’ disease in children and adolescents. Eur J Endocrinol 2004;151:155-56.
  25. Treatment of childhoodonset Graves’ disease in Japan: Results of nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. Thyroid 2007;17:67-72.
  26. Surgical management of Graves’ disease in childhood and adolescence: An institutional experience. Surgery 2006;140:1056-61.
  27. Surgical treatment of Graves’ disease in children. Thyroid 2004;14:447-52.
  28. Surgical treatment of Graves’ disease in children younger than 18 years. World J Surg 1996;20:794-99.
  29. The optimal treatment for pediatric Graves’ disease is surgery. J Clin Endocrinol Metab 2007;92:801-03.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.